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Abstract
Neutralizing antibodies that target epitopes conserved among many strains of influenza virus have
been recently isolated from humans. Here we demonstrate that adeno-associated viruses (AAV)
encoding two such broadly neutralizing antibodies are protective against diverse influenza strains.
Serum from mice that received a single intramuscular AAV injection efficiently neutralized all
H1, H2 and H5 influenza strains tested. After infection with diverse strains of H1N1 influenza,
treated mice showed minimal weight loss and lung inflammation. Protection lasted for at least 11
months after AAV injection. Notably, even immunodeficient and older mice were protected by
this method, suggesting that expression of a monoclonal antibody alone is sufficient to protect
mice from illness. If translated to humans, this prophylactic approach may be uniquely capable of
protecting immunocompromised or elderly patient populations not reliably protected by existing
vaccines.
Influenza causes seasonal epidemics that lead on average to >20,000 deaths each year in the
United States1 and many more throughout the world2. Neither immunological memory from
prior infections nor current vaccines reliably provide lasting protection against seasonal
epidemics, primarily because influenza undergoes rapid antigenic evolution that renders
immune memory obsolete3. The seasonal influenza vaccine is repeatedly reformulated in an
attempt to keep pace with viral evolution, but it provides little protection against highly
diverged influenza strains that periodically emerge from animal reservoirs to initiate human
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influenza pandemics4. Zoonotic transmissions of influenza to humans have caused four
global pandemics in the last 100 years, the most deadly of which is estimated to have killed
50 million people worldwide5. Another shortcoming of existing influenza vaccines is their
markedly reduced efficacy in the elderly6, a group that suffers nearly 90% of all deaths from
seasonal influenza1,7.
These facts underscore the need for new influenza vaccination paradigms capable of
eliciting effective immunity to many influenza strains and in all recipients, regardless of
their age or immune status. Raising hope that such vaccines might be possible, recent studies
isolated human antibodies that neutralize diverse influenza strains by binding to conserved
epitopes on the stalk of the hemagglutinin (HA) protein8–10 (Fig. 1a). In general, whereas
the HA head is highly variable, the stalk is relatively well conserved among distinct strains
of influenza. Vaccination strategies using new prime-boost regimes11 or engineered
‘headless’ HA proteins12 have elicited modest levels of broadly reactive and neutralizing
antibodies in mice, ferrets and monkeys. In addition, novel adjuvants have been developed
that can enhance the immunogenicity of influenza vaccination13. However, to be effective,
these approaches still require a functional immune response to the vaccine immunogen. As
such, it is unclear whether these strategies will be sufficient to protect vulnerable patient
populations (e.g., the elderly and immunocompromised individuals) who do not respond
effectively to immunization.
Here, we describe an alternative means of generating broadly protective humoral immunity
against influenza in both healthy and immunocompromised animals. This approach, termed
vectored immunoprophylaxis (VIP), uses adeno-associated virus (AAV) to direct muscle
tissue to express previously isolated and characterized broadly neutralizing monoclonal
antibodies. VIP with broadly neutralizing antibodies or antibody-like immunoadhesins
facilitates highly effective protection against HIV infection in humanized mice14 and simian
immunodeficiency virus infection in macaques15. Here, we use VIP to generate broadly
protective humoral immunity against diverse influenza strains (Fig. 1b) in healthy and
immunocompromised mice.
To test the ability of VIP to protect mice from influenza infection, we inserted the variable
regions from the heavy and light chains of the F10 (ref. 8) and CR6261 (refs. 9,10) broadly
neutralizing influenza antibodies (Fig. 1a) into our previously described AAV expression
system14. To improve antibody serum levels in mice, we optimized the light chain variable
region sequence (Supplementary Results). As a control, we used AAV vectors expressing
the HIV-neutralizing b12 antibody as described previously14.
A single intramuscular injection of 1 × 1011 genome copies (GC) of AAV into BALB/c
mice resulted in expression of detectable levels of human IgG in the serum within 1 week of
injection (Fig. 1c). As observed previously in immunocompetent animals14, antibody
concentrations transiently declined before increasing over the following 6–8 weeks, reaching
a plateau of 50–200 μg/ml that was maintained for the duration of the 64-week study. The
CR6261 antibody, and to a lesser degree F10 antibody, exhibited substantial mouse-to-
mouse variation in expression levels for up to 5 weeks after vector administration, but
expression was more uniform among mice at later time points (Supplementary Fig. 1a).
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To determine the breadth of neutralizing activity of sera from VIP-treated animals, we
performed in vitro neutralization assays using GFP-reporter influenza virions16, each
expressing one of five HA proteins; these HA proteins differ in sequence by up to 37%, and
originate from three different HA subtypes (H1, H2 and H5; Fig. 1b and Supplementary Fig.
2). Sera from mice expressing the b12 control antibody demonstrated no appreciable
neutralization of any of the five influenza strains tested (Fig. 1d). In contrast, sera from
animals that received VIP expressing either F10 or CR6261 neutralized multiple, often all
five, influenza strains (Fig. 1d); the potency of neutralization activity directly correlated
with the serum concentration of antibody detected by enzyme-linked immunosorbent assay
(ELISA; Supplementary Fig. 1b,c).
To determine whether VIP protected mice from influenza infection, we injected AAV
encoding b12, F10 or CR6261 into the gastrocnemius muscle of BALB/c mice; 5 weeks
later and immediately before challenge with influenza viruses we had titered previously
(Supplementary Fig. 3), we detected ~100–200 μg/ml of b12 and F10 antibodies and a broad
range of CR6261 antibody concentrations (0.1–100 μg/ml) in the serum of the injected mice
(Fig. 2a). Following intranasal administration of 10,000 plaque-forming units (PFU) of
influenza with the HA and neuraminidase (NA) from the 2009 swine-origin pandemic H1N1
strain A/California/07/2009 (CA/09), we observed dramatic weight loss in animals
expressing the control b12 antibody, but no appreciable weight loss in mice expressing the
F10 antibody (Fig. 2b). Interestingly, mice expressing CR6261 demonstrated a range of
weight loss that was inversely proportional to the serum human IgG concentration,
suggesting that a minimum serum concentration of ~7.5 μg/ml of this antibody was required
to prevent illness from CA/09 infection (Fig. 2c and Supplementary Fig. 1d). To examine
the ability of VIP to protect against infection with other influenza strains, we infected
recipients of b12 or F10 VIP with influenza carrying the HA and NA from the human
seasonal H1N1 strain A/Solomon Islands/3/2006 (SI/06) (Fig. 2d). Again, mice expressing
b12 exhibited weight loss over a period of 2 weeks. In contrast, mice expressing F10 showed
no signs of illness after SI/06 challenge. To determine the ability of VIP to protect animals
from a lethal influenza challenge, we intranasally administered 1,000 PFU of the mouse-
lethal H1N1 strain A/Puerto Rico/8/1934 (PR/34). As expected, mice expressing b12 control
rapidly lost weight to an extent that exceeded the mandated endpoint in our study within 4
days (Fig. 2e). In contrast, mice expressing F10 showed no significant signs of illness or
weight loss. Notably, when these mice were re-infected with heterologous influenza strains,
we again observed protection in all cases (Supplementary Fig. 4). Together, these findings
demonstrate that VIP-treated animals were protected against at least three diverse influenza
strains.
Next, we determined the impact of VIP-mediated antibody expression on the endogenous
humoral immune response to influenza infection. Sera from mice that expressed the b12
control antibody and that had been infected with CA/09 or SI/06 strains demonstrated strong
neutralizing activity against the infection strain, but no detectable neutralizing activity
against heterologous strains (Fig. 2f,g). This outcome was analogous to recent observations
in humans previously vaccinated with seasonal H1N1 strains (such as SI/06), who developed
antibodies against similar seasonal H1N1 strains, but produced little neutralizing antibody
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against highly diverged pandemic H1N1 strains (such as CA/09)17. In contrast, serum from
mice expressing AAV-encoded F10 or CR6261 demonstrated broad neutralizing activity
against all influenza strains tested (Fig. 2f,g). To further characterize the nature of the
endogenous influenza-neutralizing antibodies in these mice, we analyzed sera by
hemagglutinin inhibition assays (HAI), which detect antibodies specific for the variable
head (rather than the conserved stalk) of the HA protein. In sera of b12-expressing mice, we
detected endogenous HAI activity specific for the influenza strain that had infected the mice
but not for heterologous strains. In contrast, in F10-expressing mice that had been infected
with CA/09, we did not detect endogenous CA/09 HAI activity above the detection
threshold (Fig. 2h). However, in F10-expressing mice that had been infected with SI/06, we
detected endogenous SI/06-specific HAI activity (Fig. 2i). This difference may result from
the higher dose of SI/06 inoculum administered, which may have provided more HA
antigen. These results suggest that under certain conditions, protection by broadly
neutralizing antibodies can still allow the formation of endogenous humoral immunity
specific to an influenza strain.
Given the robust protection of young, immunocompetent mice treated with VIP, we sought
to determine whether such an approach would be effective in older or immunocompromised
animals. For these experiments, we employed nonobese diabetic/severe combined
immunodeficient (NOD.SCID).Il2rg−/− (NSG) mice that completely lack adaptive immune
cells and also exhibit markedly impaired innate immune responses18. To account for
variation in mouse weight, we administered AAV encoding luciferase or antibody at a dose
of 5 × 1012 GC per kg to NSG animals; we intramuscularly injected both relatively young
(14–19 weeks old) and old (46–55 weeks old) animals, and quantified expression of proteins
encoded by AAV for 4 weeks using bioluminescence imaging or ELISA (Fig. 3a,b). Young
and old mice showed similar abundance of AAV-encoded proteins at all time points,
suggesting that age did not affect the capacity for muscle-based gene expression from AAV.
To determine whether VIP was sufficient to protect these immunocompromised animals
from challenge with influenza, we administered 1,000 PFU of the lethal PR/34 strain to
young and old mice 4 weeks after AAV administration (Fig. 3c,d). In both cases, we
observed weight loss that reached the study endpoint for euthanasia in all control NSG mice
that received VIP encoding luciferase. In contrast, both young and old NSG mice that
received VIP encoding F10 were completely protected from influenza-induced weight loss,
indicating that the VIP-expressed F10 antibody alone was sufficient to protect mice in the
absence of an endogenous humoral or T-cell immune response. To further characterize the
extent to which VIP-driven F10 expression was capable of preventing illness in young NSG
mice, we contemporaneously euthanized an equal number of protected F10-expressing
animals together with luciferase-expressing animals as they reached the mandated study
endpoint and scored the level of inflammation in histological samples of lung tissue. Lungs
taken from VIP-luciferase mice 5 d after influenza infection demonstrated substantial
luminal infiltration of the bronchioles (Fig. 3e, left and Supplementary Figs. 5 and 6). In
contrast, lungs taken from VIP-F10 mice showed very low levels of inflammation and clear
bronchioles, consistent with a substantially lower level of pathology in these mice (Fig. 3e,
right and Supplementary Figs. 5 and 6). We scored lung inflammation and measured viral
RNA in lung samples taken at various time points after influenza infection, and found that
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both young and old mice exhibited the most severe inflammation and highest viral load at
earlier time points (Supplementary Fig. 7a). However, compared to VIP-luciferase mice,
VIP-F10 mice exhibited less inflammation and viral load at all time points analyzed. To
directly quantify the ability of VIP to control viral replication in NSG mice, we examined
the amount of virus present in the lungs by extracting total RNA from lung tissue harvested
at the time of death and measured viral RNA by qPCR. Lungs from mice expressing
luciferase exhibited high viral load throughout the course of the experiment (Supplementary
Fig. 7b). In contrast, F10-expressing animals analyzed at early time points contained
moderate levels of viral RNA that declined substantially over time, as a result of
dramatically reduced viral replication in the presence of F10 antibody despite the lack of
endogenous adaptive immunity.
To determine the longevity of VIP-mediated protection, we administered AAV encoding
b12 or F10 to BALB/c mice and quantified serum human IgG after 11 months. We detected
levels of b12 and F10 antibody >10 μg/ml in the sera of most of these animals (Fig. 3f). We
subsequently infected these mice intranasally with 1,000 PFU of PR/34 influenza. Mice
expressing the b12 but not the F10 antibody exhibited extensive weight loss, suggesting that
recipients of F10-encoding VIP were protected from illness (Fig. 3g). To quantify the
growth of influenza in the lungs of these mice, we euthanized animals every 3 d after
influenza infection, isolated lung tissue and measured the abundance of influenza RNA by
qPCR. We detected lower amounts of influenza RNA in the lungs of F10- compared to b12-
expressing animals, suggesting that the presence of antibody inhibited the growth of the
virus but did not completely prevent influenza infection and viral replication (Fig. 3h).
To examine the effectiveness of VIP in a large animal model of influenza, we administered
b12 or F10-expressing AAV by intramuscular injection to ferrets. Although we detected
production of human antibody in these animals, the titers achieved were ~100-fold lower
than those observed in mice, and did not result in protection against influenza challenge
(data not shown). This expression difference may be the result of the substantially reduced
half-life of human IgG1 in ferrets as compared to mice (W. Strohl, personal
communication), or the substantial immunogenicity we observed in ferrets against the
human antibody proteins (data not shown), which was not seen in mice (Supplementary Fig.
8), and which would not be predicted to affect expression in humans.
Taken together, our results demonstrate that a single intramuscular injection of AAV
encoding an influenza broadly neutralizing antibody is capable of protecting mice against
diverse influenza strains. Such broad efficacy could be especially important during
pandemics, when pre-existing immunity and conventional vaccines are unable to protect
against newly emerging HA subtypes. Recent work demonstrated that only a handful of
mutations are necessary to enable the highly pathogenic H5N1 avian strain to transmit by
airborne routes in ferrets19. If such a strain were to begin transmitting between humans,
preparation of suitable quantities of a vaccine (at least using currently approved methods)
would require many months20. Even if the HA subtype of a pandemic strain was known
before a pandemic outbreak, efforts to stockpile a traditional vaccine against this subtype
would be of uncertain value because ongoing antigenic evolution may render such vaccines
ineffective21. In contrast, VIP can administer antibodies that neutralize diverse influenza
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strains of multiple HA subtypes, including H5. In addition, because AAV is a remarkably
stable vector that can be lyophilized22, VIP may be effectively stockpiled before the start of
a pandemic. Furthermore, increasingly potent and broad influenza-neutralizing antibodies
continue to be discovered23–26, and their incorporation into VIP could extend the
effectiveness of this approach to group 2 influenza strains (such as H7) and perhaps to all
known influenza A and B strains.
The ability of VIP to protect animals lacking a properly functioning immune system is
particularly important when one considers that the vast majority of deaths from seasonal
influenza occur in the elderly1. Because current strategies to elicit protection against
influenza still require an effective immune response, elderly individuals7, and individuals
with weakened immune systems27, are less likely to be protected from infection. As VIP
results in production of broadly neutralizing antibodies without involving the immune
system, it could be employed to protect individuals who do not respond to traditional
vaccination.
Although the concentration of antibody that can be produced by VIP in humans has yet to be
determined, recent studies have demonstrated expression of therapeutic levels of factor IX
using AAV8-based vectors in human patients28. If similar clinical success is achieved for
VIP, it may provide a plausible approach to protect patients, especially those who are most
vulnerable, against both epidemic and pandemic influenza.
ONLINE METHODS
Influenza reverse-genetics plasmids
The bidirectional reverse-genetics plasmids29 from the PR/34 strain of influenza were a kind
gift from Richard Webby of St. Jude Children’s Research Hospital. The plasmids encoding
the HA and NA genes from the CA/09, SI/06 and JP/57 influenza strains were generated by
cloning the influenza genes by reverse-transcription from viral RNA obtained from the BEI
Resources reagents program into the pHW2000 plasmid, a kind gift from Yoshihiro
Kawaoka of the University of Wisconsin. The gene for the VN/04 HA was synthesized
commercially, and then cloned into this plasmid.
Influenza virus production and quantification
All influenza viruses used for the mouse infections in this study derived their six internal
genes (PB2, PB1, PA, NP, M and NS) from the A/Puerto Rico/8/1934 (H1N1) strain. The
HA and NA genes were derived from the following strains and given the following name
abbreviations:
• PR/34: the HA and NA derived from A/Puerto Rico/8/1934 (H1N1), a widely used
laboratory-adapted strain.
• CA/09: the HA and NA derived from A/California/07/2009 (H1N1), a strain
isolated early during the emergence in humans of the 2009 swine-origin H1N1
pandemic.
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• SI/06: the HA and NA derived from A/Solomon Islands/3/2006 (H1N1), a human
seasonal H1N1 vaccine strain.
The viruses were generated using the 8-plasmid bidirectional reverse-genetics system29.
Briefly, 293T and MDCK cells were maintained in DMEM (Mediatech) supplemented with
10% FBS (Omega Scientific), 100 IU/ml penicillin (Mediatech), 100 μg/ml streptomycin
(Mediatech) and 1% L-glutamine (Mediatech). Six-well tissue culture dishes (Corning)
containing co-cultures of 293T and MDCK cells were co-transfected with 250 ng of each of
the eight plasmids. At 14 h post-transfection, the media was aspirated, the cells were washed
once with PBS and influenza growth medium plus 3 μg/ml of TPCK-treated trypsin (Sigma-
Aldrich) was added to the cells. Influenza growth medium consists of Opti-MEM I
(Invitrogen) with 0.01% FBS, 0.3% bovine serum albumin (Invitrogen), 100 IU/ml
penicillin, 100 μg/ml streptomycin and 100 μg/ml calcium chloride. After 72 h, the
supernatant was collected and passaged to 15-cm dishes (Corning) containing nearly
confluent MDCK cells in influenza growth medium plus 3 μg/ml trypsin. After 72 h, the
viral supernatant was harvested and centrifuged at 2,000g for 5 min. The viral supernatant
was removed and aliquoted, and the aliquots were frozen at −80 °C.
Plaque assays
The influenza viruses were quantified by plaque assays on MDCK cells using an Avicel
microcrystalline cellulose overlay30. Briefly, MDCK cells were seeded into 6-well tissue
culture dishes. When the cells were 95% confluent, the media was removed and serial
tenfold dilutions of viral inoculum were added to a 1-ml final volume of influenza growth
medium. After 40 min, the inoculum was removed by aspiration and replaced by 4 ml of
influenza growth media with 2.4% Avicel microcrystalline cellulose and 3 μg/ml of TPCK-
treated trypsin. The plates were grown undisturbed for 3 d at 37 °C. The overlay was then
removed by aspiration, the cell layer was washed twice with PBS and the cells were stained
with 0.1% crystal violet in 20% ethanol for 15 min. This staining solution was then removed
by aspiration, the cells were washed again with PBS and the plaques were counted visually
to determine the viral titer in terms of plaque-forming units (PFU).
Mouse strains
Immunocompetent BALB/cJ (BALB/c) and immunodeficient NOD.SCID.Il2rg−/− (NSG)
mice of ~4–5 weeks of age were obtained from the Jackson Laboratory (JAX). For
experiments involving aged mice, these animals were bred and housed under barrier
conditions for the indicated period of time before influenza challenge. All experiments were
conducted in accordance with the policies of the California Institute of Technology
institutional animal care and use committee (IACUC).
Cloning of influenza-neutralizing antibodies into AAV vector
Sequences corresponding to the heavy and light chain variable regions were synthesized
(Integrated DNA Technologies) and used as templates for overlapping PCR reactions
designed to fuse the variable regions into the IgG1 constant region framework present in the
VIP expression vector as previously described14. Subsequent optimization of the light chains
Balazs et al. Page 7
Nat Biotechnol. Author manuscript; available in PMC 2014 May 22.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
required to achieve efficient expression in vivo are described in the Supplementary Results
and Supplementary Figures 9–12.
AAV production
AAV production and intramuscular injection were done as previously described14. Briefly,
1.2 × 108 293T cells were transfected with 80 μg of the vector encoding the antibody of
interest, pHELP (Applied Viromics), and pAAV 2/8 SEED (University of Pennsylvania
Vector Core) at a ratio of 0.25:1:2. Supernatant was collected 5 times over the course of 120
h. Virus was purified by PEG precipitation and cesium chloride fractionation before being
diafiltrated, concentrated and buffer exchanged through 100 k MWCO centrifuge filters
(Millipore) into buffer consisting of 100 mM sodium citrate and 10 mM Tris pH 8 before
aliquoting and storage at −80 °C. To quantify aliquots, virus was thawed, treated with
DNase and titered by qPCR as previously described14. Briefly, virus titer was determined by
quantitative PCR using a standard curve generated from previously titered, purified,
AAV2/8 encoding 4E10 antibody. Infectivity of virus aliquots was confirmed in vitro by
transducing 293T cells and quantifying antibody concentration in the cell supernatant by
ELISA.
AAV administration to mice
Before intramuscular injection, virus was thawed and diluted to the indicated dose with
buffer (100 mM sodium citrate, 10 mM Tris pH 8) in a 40 μL volume. Mice were
anesthetized by isoflorane inhalation, and virus was administered as a single injection of 40
μl into the gastrocnemius muscle.
In recipients of luciferase-encoding AAV, bioluminescent imaging was done using an IVIS
200 instrument essentially as previously described14. Bioluminescent images were taken 10
min after intraperitoneal injection of 1.5 mg D-luciferin (Gold Biotechnology). In recipients
of antibody-encoding AAV, the concentration of human IgG in mouse serum was
determined by performing ELISAs using a standard curve generated from purified Human
IgG/Kappa (Bethyl).
Infection of mice with influenza
Influenza viruses were thawed and diluted in PBS to deliver the indicated dose in a 20 μl
volume. Prior to inoculation, mice were weighed and anesthetized by intraperitoneal
injection of 200 μl of a cocktail containing 2 mg of ketamine and 0.2 mg xylazine diluted in
PBS. Mice were infected with influenza by intranasal inoculation with 20 μl of diluted virus,
10 μl per nostril. Infected mice were weighed at the same time each day.
GFP influenza virus production and quantification
PB1flank-GFP influenza viruses were generated by a previously described system in which
GFP is packaged in the PB1 segment16. PB1flank-GFP viruses were grown and assayed in
293T-CMV-PB1 and MDCK-SIAT1-CMV-PB1 cells that supplied the missing PB1 protein
in trans, as described16. PB1flank-GFP viruses were generated using the 8-plasmid
bidirectional reverse-genetics system29, but with the standard PB1 plasmid replaced by
pHH-PB1flank-eGFP16. For these viruses, the other five internal genes (PB2, PA, NP, M
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and NS) were derived from the PR/34 strain as for the viruses used in the mouse infections.
In addition to viruses with the HA and NA from PR/34, CA/09 and SI/06, we also used two
additional viruses in these assays:
• JP/57: the HA and NA derived from A/Japan/305/1957 (H2N2), an early strain
from the Asian flu pandemic.
• VN/04: the HA from A/Vietnam/1203/2004 (H5N1), a highly pathogenic avian
influenza strain. The NA for this virus was derived from the laboratory-adapted
A/WSN/1933 (H1N1) strain. The polybasic cleavage site was removed from the
HA.
PB1flank-GFP viruses were quantified by flow cytometry. MDCK-SIAT1-CMV-PB1 cells
were seeded in 12-well dishes (Corning) at 105 cells per well in 1 ml of influenza growth
medium; 8 h after seeding, viruses were diluted 1:10, 1:100 and 1:1000 in media. Wells
were infected with 50 μl of each of these dilutions. Cells were harvested 16.5 h post-
infection by incubation with 250 μl of trypsin-EDTA (Invitrogen) for 5 min, removal of
trypsin by aspiration and resuspension in 250 μl of PBS supplemented with 2% FBS and 2
μg/ml propidium iodide (Invitrogen). Samples were analyzed on a FACSCalibur flow
cytometer (Becton-Dickinson), and samples with a percentage of GFP-positive cells
between 0.3% and 3% were used to quantify viral titer. Titer was calculated from the
percentage of GFP-positive cells, the dilution factor and the total count of 105 cells per well.
Neutralization assays
Neutralization assays were performed using PB1flank-GFP influenza viruses and MDCK-
SIAT1-CMV-PB1 cells. We added 40 μl of influenza growth medium to all wells of a flat-
bottom 96-well tissue culture dish (Corning), except for row A, which received 57 μl of
media. Mouse sera samples were serially diluted by adding 3 μl of serum to the 57 μl of
influenza growth medium in row A, then performing 1:3 serial dilutions down to row G,
resulting in an initial dilution of 1:20 and final dilution of 1: 4.374 × 104. We added 2 × 104
infectious particles of PB1flank-GFP virus (as determined by flow cytometry titering) to
samples in a 20 μl volume of influenza growth medium. The mixtures of diluted serum and
virus were incubated for 1 h in a 5% CO2 incubator at 37 °C. After incubation, 2 × 104
MDCK-SIAT1-CMV-PB1 cells in a 20 μl volume of influenza growth medium were added
to all wells for an MOI of 1. A cell-only control, which received naive BALB/c mouse
serum and no virus, and a virus-only control, which received naive BALB/c mouse serum,
were included for each virus strain. Plates were incubated in a 5% CO2 incubator at 37 °C
for 18 h. Post-incubation, 40 μl of 1.5% Triton X-100 (Sigma-Aldrich) in PBS was added to
each well to give a final concentration of 0.5% Triton X-100, and plates were incubated at
room temperature for 5 min. We transferred 100 μl of each sample into opaque 96-well
plates (Corning) for reading. GFP fluorescence was quantified using a Safire2 plate reader
(Tecan) configured to read from the top with an excitation of 485 nm, emission of 515 nm,
12-nm slit widths for both excitation and emission, gain set to “optimal,” an integration time
of 500 μs and 5 reads per well. Baseline fluorescence from the cell-only control was
subtracted from all readings. Samples were normalized to the virus-only control.
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HAI assays
The HAI assay was done as described in the WHO Animal Influenza Manual
(WHO/CDS/CSR/NCS/2002.5). Chicken red blood cells (Lampire) and 96-well V-bottom
plates (Costar) were used for all assays. Hemagglutination units (HAU) of stock SI/06 and
CA/09 were determined by diluting virus 1:50 in 1× PBS, pH 7.2–7.4, then serially twofold
in a final volume of 25 μl/well. Influenza virus was diluted to 4 HAU/25 μl immediately
before use in the HAI assay. RDE (receptor-destroying enzyme) (Seiken) was reconstituted
in physiological saline (0.85% NaCl) according to manufacturer instructions. Mouse sera
was diluted 1:4 in reconstituted RDE and left overnight at 37 °C; the following day, RDE
was inactivated by incubation at 56 °C for 30 min. Sera were diluted either 1:40 (SI/06) or
1:16 (CA/09) in physiological saline and serially twofold diluted in a volume of 25 μl/well.
We added 4 HAU of virus to each well in a volume of 25 μl. Controls were run on each plate
to confirm HAU and RBC activity. After a 15-min incubation at room temperature, 50 μl of
0.5% chicken red blood cells were added to each well. Plates were incubated for 30 min at
room temperature. HAI titer was defined as the reciprocal of the greatest dilution that
completely inhibited hemagglutination of RBCs.
Histology
At the conclusion of the in vivo challenge experiments, lungs were removed from mice and
half of this tissue was immersed in 10% neutral buffered formalin for 24 h. Following
fixation, tissues were removed from formalin and placed in 70% ethanol until standard
paraffin embedding and processing. Four-micron-thick sections were then cut, and stained
with hematoxylin and eosin staining (H&E). The slides were reviewed by a pathologist
(D.S.R.) on an Olympus BX51 light microscope, and images were obtained using a SPOT
Insight Digital Camera (Diagnostic Instruments). Inflammation was scored as follows: 0 =
no to minimal inflammation; 1 = occasional infiltrates in bronchioles (less than 10% of
bronchioles); 2 = easily identified infiltrates in bronchioles (10–50% of bronchioles); 3 =
easily identified infiltrates in bronchioles with parenchymal infiltrates and/or early patchy
fibrosis; 4 = >50% of bronchioles with infiltrates, or 10–50% bronchiole involvement with
extensive necrotic epithelium in bronchioles, angionecrosis or extensive fibrosis. Scoring
was done in a blinded fashion and an ordinal scale was assumed for any statistical tests.
Relative viral quantification by qPCR
Lung tissue was homogenized in 100 μl PBS. We used 25 μl of homogenate for RNA
extraction via TRIzol Reagent (Invitrogen). Purified RNA was resuspended in nuclease-free
water, and RNA concentration was normalized to 150 ng/μl. Real-time RT-qPCR was
performed using qScript One-Step SYBR Green qRT-PCR Kit, Rox (Quanta Biosciences)
with primers designed against PR/34 M as described24 as PR8 M and an endogenous control
consisting of mouse ribosomal protein L32 with the following sequences:
Forward PR8-M: CAAGCAGCAGAGGCCATGGA, Reverse PR8-M:
GACCAGCACTGGAGCTAGGA, Forward-L32: AAGCGAAACTGGCGGAAAC
Reverse-L32: TAACCGATGTTGGGCATCAG. Samples were treated with DNase using
Turbo DNase kit (Invitrogen) and run in triplicate on an ABI 7300 Real-Time PCR System
(Life Technologies) with the following program: 50 °C for 10 min, 95 °C for 5 min, 40
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cycles of 95 °C for 15 s and 55 °C for 30 s, followed by a melt curve analysis. Each sample
was individually normalized by L32 signal to account for variation in input RNA.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
VIP results in expression of broadly neutralizing influenza antibodies in mouse serum. (a)
Crystal structure of the HA trimer from the PR/34 strain of influenza (PDB code 1RU7).
Residues are colored according to their variability in the five influenza strains used in this
study, with the most variable residues shown in red and invariant residues shown in green.
Variability is calculated as the site entropy. The binding of the VH/VL domains of the F10
(red) and CR6261 (blue) antibodies is modeled in the context of the HA trimer (PDB code
1RU7) based on alignment with PDB structures of antibodies bound to HA monomer (PDB
codes 3FKU and 3GBN, respectively). These antibodies bind to the conserved stalk rather
than the variable head of the HA. (b) Matrix of pairwise identities of the HA protein
sequences used in this study calculated as the fraction of amino acids that were identical
between two sequences and colored according to the degree of identity (green is most
similar and red is least similar). PR/34: A/PR/8/1934 (H1N1); CA/09: A/California/7/2009
(H1N1); SI/06: A/Solomon Islands/3/2006 (H1N1); JP/57: A/Japan/305/1957 (H2N2);
VN/04: A/Vietnam/1203/2004 (H5N1). (c) Human IgG in serum of BALB/c mice (as
quantified by ELISA) at indicated times after intramuscular injection of 1 × 1011 GC of
optimized AAV encoding b12, F10 or CR6261. The plot shows mean and standard error of
six recipient mice per antibody. (d) Neutralizing activity of sera taken from mice 5 weeks
after they were injected with AAV encoding b12, F10 or CR6261 (just before infection with
influenza virus) as measured against five strains of influenza (PR/34, CA/09, SI/06, JP/57
and VN/04) using a GFP reporter assay (Supplementary Fig. 2). Values are calculated as the
fold dilution of serum that resulted in 50% neutralization of influenza infection. Solid line
represents the lowest dilution tested (20-fold) and values below this line are extrapolated
from the curve fit or are plotted at a value of 15 to represent no detectable neutralization
activity. Each point represents an individual mouse serum sample tested against one strain of
influenza. Each plot contains data generated from one individual experiment, and each
experiment was performed once with the indicated number of mice.
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Figure 2.
VIP protects mice against influenza infection. (a) Total human IgG in serum was measured
by ELISA in samples taken 5 weeks after intramuscular injection of AAV encoding b12,
F10 or CR6261 (2 d before influenza infection) into BALB/c mice. Each point represents an
individual mouse. (b,c) BALB/c mice that received VIP 5 weeks prior were infected
intranasally with 1 × 104 PFU of CA/09 influenza. Weight loss was monitored for the
indicated time period in recipients of AAV encoding control (b12) or F10. The plot shows
mean and standard error of eight recipient mice per antibody (b). Correlation between
weight loss of individual mice 4 d post-infection with CA/09 and serum concentration of
CR6261 (c). (d) BALB/c mice that received VIP 5 weeks prior were infected intranasally
with 5 × 104 PFU of SI/06 influenza. Weight loss was monitored for the indicated time
period in recipients of AAV encoding control (b12) or F10. The plot shows mean and
standard error of eight recipient mice per antibody. (e) BALB/c mice that received VIP 5
weeks prior were infected intranasally with 1,000 PFU of PR/34 influenza. Survival (left)
and weight loss (right) were monitored for the indicated time period in recipients of AAV
encoding control (b12) or F10. The plots shows mean and standard error of eight recipient
mice per antibody. (f,g) Serum was taken from BALB/c mice 8 weeks after they were
injected with AAV encoding b12, F10 or CR6261, and 3 weeks after they were infected with
CA/09 (f) or SI/06 (g) influenza. In vitro neutralization of five strains of influenza (PR/34,
CA/09, SI/06, JP/57 and VN/04) by serum was detected by GFP-reporter assays. Values are
calculated as the fold dilution that resulted in 50% neutralization of influenza infection.
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Solid line represents the lowest dilution tested (20-fold dilution), and values below this line
are extrapolated from the curve fit or are plotted at a value of 15 to represent no detectable
neutralization activity. (h,i) Serum was taken from BALB/c mice 5 weeks after they were
injected with AAV encoding b12 or F10 and either just before (naive) or 3 weeks after
(post-) infection with CA/09 or SI/06. HAI performed with CA/09 virus (h) or SI/06 virus
(i). HAI titers are expressed as the highest dilution of serum that allowed complete
hemagglutination. Solid line represents the lowest dilution tested (16-fold or 40-fold dilution
for CA/09 or SI/06, respectively), and values below this line are plotted along the axis to
represent no detectable HAI activity. Each plot contains data generated from one individual
experiment, and each experiment was performed once with the indicated number of mice.
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Figure 3.
VIP protects both young and old immunodeficient mice from influenza infection. (a) Young
(3 months) or old (12 months) NSG mice were injected intramuscularly with 1 × 1011 GC of
AAV encoding luciferase. At indicated time points, luciferase was measured in vivo by
bioluminescence imaging. The plot shows mean and s.d. of eight young and eight old
recipient mice. (b) Young or old NSG mice were injected intramuscularly with 1 × 1011 GC
of AAV encoding F10. At indicated time points, serum human IgG was measured by
ELISA. The plot shows mean and s.d. of eight young and eight old recipient mice. (c,d)
Young (c) and old (d) NSG mice were injected intramuscularly with 1 × 1011 GC of AAV
encoding F10 or luciferase (Luc). Four weeks later mice were infected intranasally with
1,000 PFU of PR/34 influenza. Survival (left) and weight loss (right) were measured (n = 4–
8). Error bars, mean and s.e.m. (e) Hematoxylin and eosin staining of representative lung
sections from young NSG mice that received VIP encoding F10 or Luc, taken 5 d after
infection with 1,000 PFU of PR/34 influenza. Scale bar, 100 μM. (f–h) BALB/c mice were
injected with AAV encoding b12 or F10. Eleven months later, total human IgG in serum
was quantified by ELISA (1 d before influenza infection) (f). Each point represents an
individual mouse. (g,h) Eleven months after injection of AAV, mice were infected with
1,000 PFU of PR/34 influenza (n = 14–20). Weight loss was monitored (g). Error bars, mean
and s.e.m. Immediately following infection and every 2 d thereafter, three mice were
euthanized in each group and influenza RNA in the lungs was measured by qPCR (h).
Samples were normalized to the endogenously expressed mouse ribosomal protein L32 gene
and plotted relative to the signal of the lowest sample. Each plot contains data generated
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from one individual experiment, and each experiment was performed once with the
indicated number of mice.
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